IBANDRONATO DE SÓDIO

Опис товару

About IBANDRONATO DE SÓDIO

IBANDRONATO DE SÓDIO is a prescription medication used to treat and prevent bone loss conditions. It belongs to the bisphosphonate class of drugs, which work by inhibiting bone resorption and promoting bone density. The formulation contains ibandronate de sodium as the active component, delivered in a tablet form for oral administration. Patients typically receive the medication once a month or as directed by their healthcare provider. The product is manufactured under strict quality control standards to ensure purity and efficacy. It is indicated for use in osteoporosis, Paget’s disease, and other disorders associated with increased bone turnover. The medication is available in various strengths to accommodate individual treatment plans. Patients should follow the dosing schedule prescribed by their clinician and report any concerns or side effects promptly. The product is not intended for use in children or for conditions unrelated to bone health. Proper storage conditions and handling instructions are provided on the packaging to maintain product integrity.

Key Benefits & Uses

• Reduces the risk of fractures in patients with osteoporosis.
• Improves bone mineral density over time.
• Provides a convenient once‑monthly dosing schedule.

Active Ingredient & Action

The active ingredient, ibandronate de sodium, binds to bone mineral surfaces and inhibits osteoclast-mediated bone resorption. By decreasing bone turnover, it helps maintain skeletal strength and reduces the likelihood of pathological fractures. The drug’s pharmacokinetic profile allows for sustained action with a single monthly dose, making it easier for patients to adhere to therapy.

Important Notes

IBANDRONATO DE SÓDIO should be taken on an empty stomach with a full glass of water, at least 30 minutes before the first food, beverage, or medication of the day. Patients should remain upright for at least 30 minutes after ingestion to prevent esophageal irritation. The medication is not recommended for individuals with severe kidney impairment or those who have difficulty swallowing tablets. Patients should inform their healthcare provider of any history of esophageal disorders or gastrointestinal conditions. Regular monitoring of bone density and kidney function is advised during long‑term therapy. If any adverse reactions occur, contact a healthcare professional immediately. The product is not suitable for use during pregnancy or lactation unless specifically prescribed by a qualified medical practitioner.